Subcortical vascular encephalopathy;Subkortikale vaskuläre enzephalopathie

Therapeutische Umschau

Volumn 60, Issue 9, 2003, Pages 541-552

  Baezner, Hansjörg ^a   Daffertshofer, M ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GINKGO BILOBA EXTRACT; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NIMODIPINE; PENTOXIFYLLINE; PIRACETAM;

BODY POSTURE; BRAIN INFARCTION; CEREBROVASCULAR DISEASE; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; DISABILITY; GAIT DISORDER; HUMAN; IMMOBILIZATION; MICROANGIOPATHY; MULTIINFARCT DEMENTIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PSYCHOMOTOR ACTIVITY; REVIEW; SUBCORTICAL VASCULAR ENCEPHALOPATHY; WHITE MATTER;

EID: 0141515791     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: 10.1024/0040-5930.60.9.541     Document Type: Review

References (90)

1. Dubois MF, Hebert R. The incidence of vascular dementia in Canada: a comparison with Europe and East Asia. Neuroepidemiology. 2001; 20: 179-87.
2. Chui H. Dementia due to subcortical ischemic vascular disease. Clin Cornerstone. 2001; 3: 40-51.
3. Sacco SE, Whisnant JP, Broderick JP, Phillips SJ, O'Fallon WM. Epidemiological characteristics of lacunar infarcts in a population. Stroke. 1991; 22: 1236-41.
4. Fisher CM. Lacunes: small, deep cerebral infarcts. Neurology 1965; 15: 774-84.
5. Shinkawa A, Ueda K, Kiyohara Y, et al. Silent cerebral infarction in a community-based autopsy series in Japan. The Hisayama Study. Stroke. 1995; 26: 380-85.
6. Longstreth WT Jr, Bernick C, Manolio TA, Bryan N, Jungreis CA, Price TR. Lacunar infarcts defined by magnetic resonance imaging of 3660 elderly people: the Cardiovascular Health Study. Arch Neurol. 1998; 55: 1217-25.
7. Vermeer SE, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MM. Prevalence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke. 2002; 33: 21-5.
8. Awad IA, Spetzler RF, Hodak JA, Awad CA, Carey R. Incidental subcortical lesions identified on magnetic resonance imaging in the elderly. 1. Correlation with age and cerebrovascular risk factors. Stroke 1986; 17: 1084-9.
9. Longstreth WT Jr, Manolio TA, Arnold A, et al. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study. Stroke. 1996; 27: 1274-82.
10. Breteler MM, van Swieten JC, Bots ML et al. Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study: the Rotterdam Study. Neurology 1994 Jul; 44(7): 1246-52.
11. Englund E. Neuropathology of white matter lesions in vascular cognitive impairment. Cerebrovasc Dis. 2002; 13 Suppl 2: 11-5.
12. Inzitari D, Cadelo M, Marranci ML, Pracucci G, Pantoni L. Vascular deaths in elderly neurological patients with leukoaraiosis. J Neurol Neurosurg Psychiatry. 1997; 62: 177-81.
13. Pantoni L, Garcia JH, Gutierrez JA. Cerebral white matter is highly vulnerable to ischemia. Stroke. 1996; 27: 1641-6.
14. De Reuck J, Santens P, Strijckmans K, Lemahieu I. Cobalt-55 positron emission tomography in vascular dementia: significance of white matter changes. J Neurol Sci. 2001; 193: 1-6.
15. Fisher CM. Lacunar strokes and infarcts: a review. Neurology. 1982; 32: 871-6.
16. Bäzner H, Daffertshofer M, Konietzko M, Hennerici MG. Modification of low-frequency spontaneous oscillations in blood flow velocity in large- and small-artery disease. J Neuroimaging. 1995; 5: 212-8.
17. Wardlaw JM, Sandercock PA, Dennis MS, Starr J, Kalimo H. Is breakdown of the blood-brain barrier responsible for lacunar stroke, leukoaraiosis, and dementia? Stroke. 2003 Mar; 34: 806-12.
18. Ma KC, Olsson Y. The role of chronic brain edema in the formation of lacunes in Binswanger's encephalopathy. Cerebrovasc Dis 1997; 7: 324-31.
19. Johannson BB. White matter changes and blood-brain barrier dysfunction. In: Pantoni L, Inzitari D, Wallin A (Eds): The Matter of White Matter. Utrecht, Academic Pharmaceutical Productions, 2000, Vol. 10: 313-23.
20. Wallin A, Blennow K, Rosengren L. Cerebrospinal fluid markers of pathogenetic processes in vascular dementia, with special reference to the subcortical subtype. Alzheimer Dis Assoc Disord. 1999; 13 Suppl 3: S102-5.
21. Brown WR, Moody DM, Challa VR, Thore CR, Anstrom JA. Apoptosis in leukoaraiosis lesions. J Neurol Sci. 2002; 203-4: 169-71.
22. Joutel A, Corpechot C, Ducros A, et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature. 1996; 383: 707-10.
23. Garcin R, Lapresle J, Lyon G. Encéphalopathie sous-corticale chronique de Binswanger. Étude anatomique de trois observations. Rev Neurol 1960; 102: 423-39.
24. Furuta A, Ishii N, Nishihara Y, Horie A. Medullary arteries in aging and dementia. Stroke. 1991; 22: 442-6.
25. Fassbender K, Mielke O, Bertsch T, Nafe B, Froschen S, Hennerici M. Homocysteine in cerebral macroangiopathy and microangiopathy. Lancet. 1999; 353: 1586-7.
26. Ravens JR. Vascular changes in the human senile brain. Adv Neurol. 1978; 20: 487-501.
27. Olsson Y, Brun A, Englund E. Fundamental pathological lesions in vascular dementia. Acta Neurol Scand Suppl. 1996; 168: 31-8.
28. Roman GC, Royall DR. Executive control function: a rational basis for the diagnosis of vascular dementia. Alzheimer Dis Assoc Disord. 1999 Oct-Dec; 13 Suppl 3: 69-80.
29. Hennerici M, Bäzner H, Daffertshofer M. White matter changes: symptoms and signs In: Pantoni L, Inzitari D, Wallin A (Eds): The Matter of White Matter. Utrecht, Academic Pharmaceutical Productions, 2000, Vol. 10: 55-80.
30. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci. 1986; 9: 357-81.
31. Mega MS, Cummings JL. Frontal-subcortical circuits and neuropsychiatric disorders. J Neuropsychiatry Clin Neurosci. 1994; 6: 358-70.
32. Royall DR. Executive cognitive impairment: a novel perspective on dementia. Neuroepidemiology. 2000; 19: 293-9.
33. Wallin A, Edman A, Blennow K, et al. Stepwise comparative status analysis (STEP): a tool for identification of regional brain syndromes in dementia. J Geriatr Psychiatry Neurol. 1996; 9: 185-99.
34. FitzGerald PM, Jankovic J. Lower body parkinsonism: evidence for vascular etiology. Mov Disord. 1989; 4: 249-60.
35. Nutt JG, Marsden CD, Thompson PD. Human walking and higher-level gait disorders, particularly in the elderly. Neurology. 1993; 43: 268-79.
36. De Reuck J, Siau B, Decoo D, et al. Parkinsonism in patients with vascular dementia: clinical, computed- and positron emission-tomographic findings. Cerebrovasc Dis. 2001; 11: 51-8.
37. Demirkiran M, Bozdemir H, Sarica Y. Vascular parkinsonism: a distinct, heterogeneous clinical entity. Acta Neurol Scand. 2001; 104: 63-7.
38. Bäzner H, Oster M, Daffertshofer M, Hennerici M. Assessment of gait in subcortical vascular encephalopathy by computerized analysis: a cross-sectional and longitudinal study. J Neurol. 2000; 247: 841-9.
39. Tatemichi TK, Desmond DW, Prohovnik I. Strategic infarcts in vascular dementia. A clinical and brain imaging experience. Arzneimittelforschung. 1995; 45: 371-85.
40. Erkinjuntti T, Hachinski VC: Rethinking vascular dementia. Cerebrovasc Dis 1993; 3: 3-23.
41. Tatemichi TK: How acute brain failure becomes chronic. A view of the mechanisms and syndromes of dementia related to stroke. Neurology 1990; 40: 1652-9.
42. Chui HC: Dementia: A review emphasizing clinicopathologic correlation and brain- behavior relationships. Arch Neurol 1989; 46: 806-814.
43. Erkinjuntti T: Cerebrovascular dementia. Pathophysiology, diagnosis and treatment. CNS Drugs 1999; 12: 35-48.
44. Wallin A, Blennow K: The clinical diagnosis of vascular dementia. Dementia 1994; 5: 181-4.
45. Wetterling T, Kanitz RD, Borgis KJ: Comparison of different diagnostic criteria for vascular dementia (ADDTC, DSM-IV, ICD-10, NINDS-AIREN). Stroke 1996; 27: 30-6.
46. Erkinjuntti T, Ostbye T, Steenhuis R, Hachinski V: The effect of different diagnostic criteria on the prevalence of dementia. N Engl J Med 1997; 337: 1667-74.
47. Pohjasvaara T, Mäntylä R, Ylikoski R, Aronen HJ, Kaste M, Erkinjuntii T: Comparison of different clinical criteria for the vascular cause of vascular dementia (ADDTC, DSM-III, DSM-IV, ICD-10, NINDS-AIREN). Stroke 2000; 31: 2952-7.
48. Inzitari D, Erkinjuntti T, Wallin A, del Ser T, Romanelli M, Pantoni L: Subcortical vascular dementia as a specific target for clinical trials. Ann NY Acad Sci 2000; 903: 510-21.
49. Erkinjuntti T, Inzitari D, Pantoni L, et al. Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl. 2000; 59: 23-30.
50. Roman GC: Senile dementia of the Binswanger type. A vascular form of dementia in the elderly. JAMA 1987; 258: 1782-8.
51. Griffiths DJ, McCracken PN, Harrison GM, et al. Cerebral aetiology of urinary urge incontinence in elderly people. Age Ageing. 1994 May; 23(3): 246-50.
52. Athwal BS, Berkley KJ, Hussain I, et al. Brain responses to changes in bladder volume and urge to void in healthy men. Brain. 2001; 124: 369-77.
53. Barkhof F, Scheltens P. Imaging of white matter lesions. Cerebrovasc Dis. 2002; 13 Suppl 2: 21-30.
54. Wahlund LO, Barkhof F, Fazekas F, et al. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke. 2001; 32: 1318-22.
55. Kapeller P, Barber R, Vermeulen RJ, et al. Visual rating of age-related white matter changes on magnetic resonance imaging: scale comparison, interrater agreement, and correlations with quantitative measurements. Stroke. 2003 Feb; 34(2): 441-5.
56. Looi JC, Sachdev PS. Differentiation of vascular dementia from AD on neuropsychological tests. Neurology. 1999; 53: 670-8.
57. Roman GC, Erkinjuntti T, Wallin A, Pantoni L, Chui HC. Subcortical ischaemic vascular dementia. Lancet Neurology 2002; 1: 426-36.
58. Ferris SH. Cognitive outcome measures [for VaD]. Alzheimer Dis Assoc Disord. 1999; 13 Suppl 3: S140-2.
59. Guralnik JM, Simonsick EM, Ferrucci L, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol 1994; 49: M85-94
60. Marti-Fabregas J, Valencia C, Pujol J, Garcia-Sanchez C, Marti-Vilalta JL. Fibrinogen and the amount of leukoaraiosis in patients with symptomatic small-vessel disease. Eur Neurol. 2002; 48: 185-90.
61. Tomimoto H, Akiguchi I, Wakita H, Osaki A, Hayashi M, Yamamoto Y. Coagulation activation in patients with Binswanger disease. Arch Neurol. 1999; 56: 1104-8.
62. Hassan A, Hunt BJ, O'Sullivan M, et al. Markers of endothelial dysfunction in lacunar infarction and ischaemic leukoaraiosis. Brain. 2003 Feb; 126: 424-32.
63. McCawley LJ, Matrisian LM. Matrix metalloproteinases: they're not just for matrix anymore! Curr Opin Cell Biol 2001; 13: 534-40.
64. Bret P, Guyotat J, Chazal J. Is normal pressure hydrocephalus a valid concept in 2002? A reappraisal in five questions and proposal for a new designation of the syndrome as "chronic hydrocephalus". J Neurol Neurosurg Psychiatry. 2002; 73: 9-12.
65. T. Erkinjuntti. Cerebrovascular dementia. Pathophysiology, diagnosis and treatment. CNS Drugs 1999; 12: 35-48.
66. Skoog I. Status of risk factors for vascular dementia. Neuroepidemiology 1998; 17: 2-9.
67. Williams PS, Rands G, Orrel M, Spector A. Aspirin for vascular dementia. Cochrane Database Syst Rev. 2000; (4): CD001296.
68. Longstreth WT Jr, Bernick C, Manolio TA, Bryan N, Jungreis CA, Price TR. Lacunar infarcts defined by magnetic resonance imaging of 3660 elderly people: the Cardiovascular Health Study. Arch Neurol. 1998; 55: 1217-25.
69. Zunker P, Schick A, Buschmann HC, et al. Hyperinsulinism and cerebral microangiopathy. Stroke. 1996; 27: 219-23.
70. Bots ML, van Swieten JC, Breteler MM, et al. Cerebral white matter lesions and atherosclerosis in the Rotterdam Study. Lancet. 1993; 341: 1232-7.
71. Manolio TA, Kronmal RA, Burke GL, et al. Magnetic resonance abnormalities and cardiovascular disease in older adults. The Cardiovascular Health Study. Stroke. 1994 Feb; 25(2): 318-27.
72. Schmidt R, Fazekas F, Kleinert G, et al. Magnetic resonance imaging signal hyperintensities in the deep and subcortical white matter. A comparative study between stroke patients and normal volunteers. Arch Neurol. 1992; 49: 825-7.
73. Kertesz A, Black SE, Tokar G, Benke T, Carr T, Nicholson L Periventricular and subcortical hyperintensities on magnetic resonance imaging. 'Rims, caps, and unidentified bright objects'. Arch Neurol. 1988; 45: 404-8.
74. Forette F, Seux ML, Staessen JA, et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med. 2002; 162: 2046-52.
75. Bosch J, Yusuf S, Pogue J, et al. Use of ramipril in preventing stroke: double blind randomised trial. BMJ. 2002; 324: 699-702.
76. Schmidt R, Hayn M, Fazekas F, Kapeller P, Esterbauer H. Magnetic resonance imaging white matter hyperintensities in clinically normal elderly individuals. Correlations with plasma concentrations of naturally occurring antioxidants. Stroke. 1996; 27: 2043-7.
77. Dib M. Methodological issues and therapeutic perspectives in vascular dementia: a review. Arch Gerontol Geriatr 2001; 33: 71-80.
78. Birks J, Grimley EV, Van Dongen M. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2002; (4): CD003120.
79. Flicker L, Grimley Evans G. Piracetam for dementia or cognitive impairment. Cochrane Database Syst Rev. 2001; (2): CD001011.
80. Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001; 56: 1154-66.
81. Orgogozo JM, Rigaud AS, Stoffler A, Mobius HJ, Forette F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke. 2002; 33: 1834-9.
82. Wilcock G, Mobius HJ, Stoffler A. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol. 2002; 17: 297-305.
83. Kumar V, Anand R, Messina J, Hartman R, Veach J. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. Eur J Neurol 2000; 7: 159-69.
84. Pratt RD, Perdomo CA. Donepezil-treated patients with probable vascular dementia demonstrate cognitive benefits. Ann NY Acad Sci. 2002; 977: 513-22.
85. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet. 2002; 359: 1283-90.
86. Erkinjuntti T. Cognitive decline and treatment options for patients with vascular dementia. Acta Neurol Scand Suppl. 2002; 178: 15-8.
87. Verghese J, Lipton RB, Hall CB, Kuslansky G, Katz MJ, Buschke H. Abnormality of gait as a predictor of non-Alzheimer's dementia. N Engl J Med. 2002; 347: 176-8.
88. Boyle PA, Cohen RA, Paul R, Moser D, Gordon N. Cognitive and motor impairments predict functional declines in patients with vascular dementia. Int J Geriatr Psychiatry. 2002; 17: 164-9.
89. Baezner H, Oster M, Henning O, Cohen S, Hennerici MG. Amantadine increases gait steadiness in frontal gait disorder due to subcortical vascular encephalopathy: a double-blind randomized placebo-controlled trial based on quantitative gait analysis. Cerebrovasc Dis. 2001; 11: 235-44.
90. Erkinjuntti T: Subcortical vascular dementia. Cerebrovasc Dis 2002; 13 (suppl 2): 58-60.